Research Snappy
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News
No Result
View All Result
Research Snappy
No Result
View All Result

Astrazeneca PLC (NYSE:AZN), Gilead Sciences, Inc. (NASDAQ:GILD) – Pharma Sector Did Its Job With COVID-19 Vaccine: Barclays Analyst

researchsnappy by researchsnappy
November 21, 2020
in Healthcare Research
0
Astrazeneca PLC (NYSE:AZN), Gilead Sciences, Inc. (NASDAQ:GILD) – Pharma Sector Did Its Job With COVID-19 Vaccine: Barclays Analyst
400
SHARES
2.4k
VIEWS
Share on FacebookShare on Twitter

The pharmaceutical industry has succeeded in doing its job in manufacturing multiple vaccines for the novel coronavirus, and it’s “now in the hands” of government authorities to manage the distribution, Emily Field, head of European pharmaceutical research at Barclays, Emily Field said Friday on CNBC’s “Squawk Box Europe.”

Price Not A Factor: Early indications suggest AstraZeneca plc (NASDAQ: AZN) and Johnson & Johnson’s (NYSE: JNJ) vaccine will cost $3 to $5, while pricing for Pfizer Inc. (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) could reach $40 on the high end.

Pricing is unlikely to be a determining factor as governments are prioritizing getting as many people vaccinated as quickly as possible given a limited initial supply, Field said. 

“As long as we know it is safe and efficacious, I don’t think that price is going to be a determining factor,” she said.

Convincing The Public: The general public should be reminded that results from vaccine trials are “the best we could have hoped for,” the Barclays analyst said. 

Public opinion and attitudes toward the vaccine could be impacted by mixed messages from the World Health Organization and the U.S. FDA related to Gilead Sciences, Inc. (NASDAQ: GILD), she said.

Specifically, the WHO was encouraging doctors worldwide not to use Gilead’s remdesivir as a treatment against the coronavirus.

Related Link: Pfizer, BioNTech File First For Emergency Use Authorization Of Coronavirus Vaccine

These public disputes may help skeptics prove their point that the medical community isn’t as confident as they appear to be, Field said. 

To counter this argument, it should be noted remdesivir was designed years before the start of the pandemic to treat other viruses such as Ebola, the analyst said.

AstraZeneca was quick to design a new antibody treatment for COVID-19, she said. 

“In essence, these older drugs really weren’t meant to treat COVID-19, so it makes sense that there is some debate over their efficacy in treating this disease.” 

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Previous Post

Milwaukee sees slight drop in COVID-19 cases, positivity

Next Post

Vallejo’s Factory_OS gets $55M in new funding to increase production of affordable apartments, build housing research center

Next Post
Vallejo’s Factory_OS gets $55M in new funding to increase production of affordable apartments, build housing research center

Vallejo’s Factory_OS gets $55M in new funding to increase production of affordable apartments, build housing research center

Research Snappy

Category

  • Advertising Research
  • Consumer Research
  • Data Analysis
  • Healthcare Research
  • Investment Research
  • News
  • Top Company News

HPIN International Financial Platform Becomes a New Benchmark for India’s Digital Economy

Top 10 Market Research Companies in the world

3 Best Market Research Certifications in High Demand

  • Privacy Policy
  • Terms of Use
  • Antispam
  • DMCA
  • Contact Us

© 2025 researchsnappy.com

No Result
View All Result
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News

© 2025 researchsnappy.com